Skip to content

Safety and Efficacy of the Penumbra™ System in Acute Middle Cerebral Artery (MCA) Stroke

Randomized Clinical Trial Comparing Intravenous Thrombolysis With Thrombectomy by the Penumbra™ System in Patients With Middle Cerebral Artery Stem Occlusion - Pilot Study

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01133223
Enrollment
0
Registered
2010-05-28
Start date
2010-05-31
Completion date
2015-09-30
Last updated
2015-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Stroke, mecanical thrombectomy

Brief summary

Stroke prognosis is intimately related to reperfusion. Reperfusion in acute setting can be achieved with different strategies - varying from intravenous rtPA from mechanical thrombectomy. Recently, interventional approaches have been gaining attention and playing an increasing role in stroke care. However, no solid scientifical data is available to date. The investigators want do conduct a pilot trial to test if the use of the Penumbra™ System can improve clinical outcomes in a specific stroke setting.

Interventions

DEVICEPenumbra™ System

Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)

Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patient enrolled in acute ischemic stroke protocol * Up to 3,5h from symptoms onset * Clinical findings compatible with middle cerebral artery syndrome * Angiotomographic evidence of proximal middle cerebral artery occlusion

Exclusion criteria

* NIHSS \< 10 * Overt contraindication to thrombolysis or angiopgraphy * Disagreement with informed consent term or refusal to participate

Design outcomes

Primary

MeasureTime frame
Functional independence (modified Rankin Scale 0-2)3 months

Secondary

MeasureTime frame
Minimal or no disability (modified Rankin Scale 0-1)3 months
Overall mortality7 days and 3 months
Symptomatic cerebral bleeding rate48 hours, 7 days and 3 months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026